Oral Session 3
Mechanical circulatory support

[ISPHLT-OS3-2] Our experience of the use of implantable ventricular assist device

^○Yuki Ito¹, Heima Sakaguchi¹, Hikari Miike¹, Hajime Ichikawa², Tomoyuki Fujita³, Norihide Fukushima⁴ (1.Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Japan, 2.Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Japan, 3.Department of Cardiac Surgery, National Cerebral and Cardiovascular Ce)

Background: Evolution and miniaturization have increased the use of ventricular assist device (VAD) in the pediatric and congenital heart disease (CHD) population. But we have few experiences of VAD implantation against such patients in Japan.
Methods: Data of all consecutive pediatric and ACHD patients with implantable VAD from 2016 to 2021 were retrospectively reviewed and we examined several factors associated with the prognosis.
Results: A total of 11 patients underwent VAD implantation. The etiology of heart failure was dilated cardiomyopathy in four patients, ischemic cardiomyopathy in one, and CHD in six. All cases of CHD were adults. The etiology of CHD was transposition of the great arteries (TGA) after Mustard operation in two, TGA after arterial switch operation in one, congenitally corrected TGA (ccTGA) after anatomical repair in two, and ccTGA after functional repair in one. Type of VAD were HeartMate3 in five, HeartMate2 in three, HVAD in two, and Jarvik 2000 in one. One patient underwent heart transplantation, eight patients have been waiting for transplantation, and two patients who had heart failure with severe diastolic dysfunction died.
Discussion:Cases with severe diastolic function had poor prognosis. Considering indication of VAD implantation is important and we should examine therapeutic strategy conforming to its etiology.